BMS-986368 for Agitation in Alzheimer's Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Age
- 55 – 90
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 120 (estimated)
- Sponsor
- Celgene · Industry
This trial is looking for people with Alzheimer's disease who experience agitation. Participants will take a medication called BMS-986368 and help researchers understand its effects.
You may be able to join if
- I have been diagnosed with Alzheimer's disease.
- I have agitation that started at least four weeks ago.
- I have a Mini-Mental State Examination score of 24 or lower.
- I have an agitation/aggression score of 4 or higher.
- I have a stable living environment for at least 6 weeks.
- I can move around on my own or with a mobility aid.
You may not be able to join if
- I have significant delusions or hallucinations that need hospitalization.
- I have a history of bipolar disorder or schizophrenia.
- I had a major depressive episode with psychotic features in the last 12 months.
- I had delirium within 30 days before the screening.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Loading trial locations…
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT